Furiex Pharmaceuticals, Inc. Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced its late-breaking abstract describing results from the Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, its investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome, was accepted for presentation at the upcoming American College of Gastroenterology Annual Scientific Meeting in Washington, DC. Dr. Charles Randall, clinical professor of medicine at the University of Texas Health Science Center of San Antonio and an investigator in this recently completed trial, will present the results at the Plenary Session 2, on November 1, 2011 at the Gaylord National Hotel and Convention Center in Washington, DC.